Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
Phase of Trial: Phase IV
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Apixaban (Primary) ; Aspirin
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms ARTESiA
- 10 Jun 2017 Biomarkers information updated
- 24 May 2017 Planned End Date changed from 1 Jul 2019 to 1 Apr 2021.
- 24 May 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Dec 2020.